TABLE 1

Population, Intervention, Comparator, Outcome questions that were discussed during the guideline development group meeting on the treatment of drug-resistant tuberculosis (TB)

Question 1In MDR/RR-TB patients, does an all-oral treatment regimen lasting 9–12 months and including bedaquiline safely improve outcomes when compared with other regimens conforming to WHO guidelines?
Question 2In XDR-TB patients or patients who are treatment intolerant or with nonresponsive MDR-TB, does a treatment regimen lasting 6–9 months composed of bedaquiline, pretomanid and linezolid safely improve outcomes when compared with other regimens conforming to WHO guidelines?
Question 3In MDR/RR-TB patients, does a treatment regimen containing bedaquiline for >6 months safely improve outcomes when compared with bedaquiline for ≤6 months as part of longer
regimens otherwise conforming to WHO guidelines?
Question 4In MDR/RR-TB patients, does concurrent use of bedaquiline and delamanid safely improve outcomes when compared with other treatment regimen options otherwise conforming to WHO guidelines?

MDR: multidrug-resistant; RR: rifampicin-resistant; XDR: extensively drug-resistant; WHO: World Health Organization.